Renhe Pharmacy Co., Ltd. Logo

Renhe Pharmacy Co., Ltd.

000650.SZ

(2.5)
Stock Price

5,89 CNY

7.74% ROA

8.98% ROE

16.78x PER

Market Cap.

9.192.681.600,00 CNY

4.34% DER

3.01% Yield

11.71% NPM

Renhe Pharmacy Co., Ltd. Stock Analysis

Renhe Pharmacy Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Renhe Pharmacy Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

4 ROE

The stock's ROE falls within an average range (11.21%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (9.71%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 PBV

The stock's PBV ratio (1.64x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

7 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (41), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Renhe Pharmacy Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Renhe Pharmacy Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Renhe Pharmacy Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Renhe Pharmacy Co., Ltd. Revenue
Year Revenue Growth
1993 126.253.226
1994 132.181.241 4.48%
1995 160.833.756 17.81%
1996 169.474.028 5.1%
1997 136.257.354 -24.38%
1998 192.647.237 29.27%
1999 236.033.886 18.38%
2000 236.128.941 0.04%
2001 225.103.800 -4.9%
2002 220.813.281 -1.94%
2003 281.620.861 21.59%
2004 280.391.321 -0.44%
2005 267.138.389 -4.96%
2006 24.943.408 -970.98%
2007 778.664.871 96.8%
2008 876.460.543 11.16%
2009 982.736.827 10.81%
2010 1.366.781.296 28.1%
2011 2.207.708.539 38.09%
2012 2.087.519.161 -5.76%
2013 1.799.375.836 -16.01%
2014 2.253.212.435 20.14%
2015 2.523.842.663 10.72%
2016 3.567.078.260 29.25%
2017 3.843.771.351 7.2%
2018 4.403.423.474 12.71%
2019 4.581.171.579 3.88%
2020 4.106.104.187 -11.57%
2021 4.935.755.208 16.81%
2022 5.153.215.069 4.22%
2023 4.547.095.221 -13.33%
2023 4.982.965.483 8.75%
2024 4.460.616.252 -11.71%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Renhe Pharmacy Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 4.643.825 100%
2011 1.735.252 -167.62%
2012 4.111.460 57.79%
2013 13.589.052 69.74%
2014 9.385.336 -44.79%
2015 12.847.322 26.95%
2016 21.636.444 40.62%
2017 35.916.602 39.76%
2018 31.077.317 -15.57%
2019 38.041.575 18.31%
2020 39.794.065 4.4%
2021 52.143.771 23.68%
2022 50.536.984 -3.18%
2023 30.218.967 -67.24%
2023 43.838.600 31.07%
2024 42.127.572 -4.06%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Renhe Pharmacy Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 5.785.105
1994 7.067.975 18.15%
1995 7.327.200 3.54%
1996 6.876.750 -6.55%
1997 4.973.578 -38.27%
1998 5.391.897 7.76%
1999 6.483.998 16.84%
2000 12.447.696 47.91%
2001 12.165.336 -2.32%
2002 16.012.170 24.02%
2003 133.328.642 87.99%
2004 68.966.988 -93.32%
2005 128.104.610 46.16%
2006 -209.766.334 161.07%
2007 33.258.729 730.71%
2008 27.228.355 -22.15%
2009 44.881.115 39.33%
2010 21.073.712 -112.97%
2011 17.880.730 -17.86%
2012 39.176.925 54.36%
2013 36.482.448 -7.39%
2014 36.234.267 -0.68%
2015 23.143.970 -56.56%
2016 27.948.703 17.19%
2017 58.259.165 52.03%
2018 85.460.635 31.83%
2019 78.794.925 -8.46%
2020 52.840.948 -49.12%
2021 56.761.250 6.91%
2022 68.598.938 17.26%
2023 791.196.447 91.33%
2023 63.622.026 -1143.59%
2024 -189.628.174 133.55%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Renhe Pharmacy Co., Ltd. EBITDA
Year EBITDA Growth
1993 -6.835.586
1994 -8.765.845 22.02%
1995 -8.557.208 -2.44%
1996 31.527.550 127.14%
1997 21.299.995 -48.02%
1998 50.100.518 57.49%
1999 50.345.325 0.49%
2000 43.326.863 -16.2%
2001 25.343.948 -70.96%
2002 55.282.218 54.16%
2003 -53.740.712 202.87%
2004 -21.479.456 -150.2%
2005 -87.478.498 75.45%
2006 177.172.857 149.37%
2007 68.320.003 -159.33%
2008 107.650.232 36.54%
2009 233.447.883 53.89%
2010 317.694.946 26.52%
2011 422.446.885 24.8%
2012 406.789.085 -3.85%
2013 371.825.920 -9.4%
2014 516.226.606 27.97%
2015 637.665.584 19.04%
2016 670.697.809 4.93%
2017 676.363.814 0.84%
2018 900.827.650 24.92%
2019 932.982.484 3.45%
2020 938.330.890 0.57%
2021 1.116.220.551 15.94%
2022 1.126.832.891 0.94%
2023 1.197.790.657 5.92%
2023 1.090.185.050 -9.87%
2024 1.158.749.800 5.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Renhe Pharmacy Co., Ltd. Gross Profit
Year Gross Profit Growth
1993 40.867.735
1994 46.690.630 12.47%
1995 51.844.672 9.94%
1996 39.517.863 -31.19%
1997 27.874.994 -41.77%
1998 45.158.271 38.27%
1999 45.651.068 1.08%
2000 40.543.964 -12.6%
2001 -8.932.088 553.91%
2002 31.619.419 128.25%
2003 42.038.855 24.79%
2004 -980.266 4388.52%
2005 5.613.359 117.46%
2006 -10.445.434 153.74%
2007 297.138.638 103.52%
2008 431.319.499 31.11%
2009 671.127.650 35.73%
2010 706.975.106 5.07%
2011 869.266.592 18.67%
2012 822.273.042 -5.72%
2013 799.863.774 -2.8%
2014 1.030.466.567 22.38%
2015 1.124.631.898 8.37%
2016 1.306.026.714 13.89%
2017 1.496.560.840 12.73%
2018 1.892.809.221 20.93%
2019 1.938.520.793 2.36%
2020 1.650.024.777 -17.48%
2021 1.874.339.961 11.97%
2022 1.886.938.521 0.67%
2023 1.736.657.187 -8.65%
2023 1.759.006.979 1.27%
2024 1.712.302.644 -2.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Renhe Pharmacy Co., Ltd. Net Profit
Year Net Profit Growth
1993 12.805.172
1994 13.456.599 4.84%
1995 17.510.913 23.15%
1996 14.978.866 -16.9%
1997 16.375.472 8.53%
1998 28.304.469 42.15%
1999 27.726.367 -2.09%
2000 21.787.844 -27.26%
2001 -12.713.183 271.38%
2002 8.839.478 243.82%
2003 -100.484.243 108.8%
2004 -69.127.115 -45.36%
2005 -129.943.353 46.8%
2006 130.301.621 199.73%
2007 39.170.351 -232.65%
2008 70.161.003 44.17%
2009 165.493.385 57.6%
2010 219.530.952 24.62%
2011 300.353.372 26.91%
2012 255.461.059 -17.57%
2013 194.182.835 -31.56%
2014 300.907.595 35.47%
2015 391.303.600 23.1%
2016 372.380.254 -5.08%
2017 380.226.696 2.06%
2018 506.464.000 24.93%
2019 537.826.647 5.83%
2020 580.180.490 7.3%
2021 665.024.502 12.76%
2022 574.430.143 -15.77%
2023 735.306.822 21.88%
2023 567.257.498 -29.62%
2024 639.516.672 11.3%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Renhe Pharmacy Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 1 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Renhe Pharmacy Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 1.436.397
1999 31.295.916 95.41%
2000 -130.113.241 124.05%
2001 -26.826.341 -385.02%
2002 20.795.154 229%
2003 -66.707.572 131.17%
2004 -6.001.603 -1011.5%
2005 -23.553.431 74.52%
2006 197.104.503 111.95%
2007 30.838.043 -539.16%
2008 50.087.151 38.43%
2009 142.030.570 64.73%
2010 101.493.416 -39.94%
2011 65.459.424 -55.05%
2012 -58.129.433 212.61%
2013 119.270.844 148.74%
2014 227.736.781 47.63%
2015 357.352.014 36.27%
2016 462.162.616 22.68%
2017 454.278.639 -1.74%
2018 499.331.551 9.02%
2019 549.867.473 9.19%
2020 652.921.778 15.78%
2021 277.934.729 -134.92%
2022 1.048.890.047 73.5%
2023 -37.031.314 2932.44%
2023 390.893.766 109.47%
2024 151.782.308 -157.54%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Renhe Pharmacy Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 14.475.282
1999 67.372.352 78.51%
2000 -37.079.124 281.7%
2001 3.416.243 1185.38%
2002 27.992.694 87.8%
2003 -50.139.210 155.83%
2004 17.553.628 385.63%
2005 -17.627.825 199.58%
2006 235.279.503 107.49%
2007 35.397.397 -564.68%
2008 62.141.462 43.04%
2009 200.579.110 69.02%
2010 130.072.804 -54.21%
2011 166.926.090 22.08%
2012 183.966.860 9.26%
2013 213.355.358 13.77%
2014 365.274.345 41.59%
2015 434.765.147 15.98%
2016 522.083.291 16.72%
2017 497.855.600 -4.87%
2018 569.454.435 12.57%
2019 693.970.679 17.94%
2020 871.131.642 20.34%
2021 777.717.530 -12.01%
2022 1.269.978.522 38.76%
2023 0 0%
2023 577.442.920 100%
2024 253.597.655 -127.7%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Renhe Pharmacy Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 13.038.885
1999 36.076.435 63.86%
2000 93.034.117 61.22%
2001 30.242.584 -207.63%
2002 7.197.539 -320.18%
2003 16.568.362 56.56%
2004 23.555.231 29.66%
2005 5.925.606 -297.52%
2006 38.175.000 84.48%
2007 4.559.353 -737.29%
2008 12.054.310 62.18%
2009 58.548.539 79.41%
2010 28.579.387 -104.86%
2011 101.466.665 71.83%
2012 242.096.293 58.09%
2013 94.084.514 -157.32%
2014 137.537.563 31.59%
2015 77.413.133 -77.67%
2016 59.920.674 -29.19%
2017 43.576.961 -37.51%
2018 70.122.883 37.86%
2019 144.103.206 51.34%
2020 218.209.863 33.96%
2021 499.782.800 56.34%
2022 221.088.474 -126.06%
2023 37.031.314 -497.03%
2023 186.549.154 80.15%
2024 101.815.347 -83.22%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Renhe Pharmacy Co., Ltd. Equity
Year Equity Growth
1993 12.920.775
1994 48.651.097 73.44%
1995 51.277.734 5.12%
1996 143.068.090 64.16%
1997 159.443.562 10.27%
1998 233.763.256 31.79%
1999 261.489.823 10.6%
2000 345.323.268 24.28%
2001 331.582.984 -4.14%
2002 338.738.220 2.11%
2003 238.171.849 -42.22%
2004 169.044.734 -40.89%
2005 46.883.934 -260.56%
2006 194.707.013 75.92%
2007 235.439.431 17.3%
2008 305.600.435 22.96%
2009 857.162.389 64.35%
2010 912.048.615 6.02%
2011 1.142.109.079 20.14%
2012 1.712.065.217 33.29%
2013 1.938.853.553 11.7%
2014 2.162.045.529 10.32%
2015 2.600.859.640 16.87%
2016 3.204.481.497 18.84%
2017 3.472.444.973 7.72%
2018 3.914.983.963 11.3%
2019 4.351.956.409 10.04%
2020 5.610.515.757 22.43%
2021 5.926.892.730 5.34%
2022 6.421.788.185 7.71%
2023 6.654.500.784 3.5%
2023 6.801.422.119 2.16%
2024 7.031.044.106 3.27%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Renhe Pharmacy Co., Ltd. Assets
Year Assets Growth
1993 129.663.681
1994 172.734.622 24.93%
1995 170.813.041 -1.12%
1996 269.739.196 36.67%
1997 278.202.118 3.04%
1998 360.063.240 22.74%
1999 476.214.275 24.39%
2000 651.614.225 26.92%
2001 711.942.334 8.47%
2002 759.663.704 6.28%
2003 679.381.169 -11.82%
2004 600.725.982 -13.09%
2005 455.999.023 -31.74%
2006 271.721.020 -67.82%
2007 308.483.317 11.92%
2008 437.801.718 29.54%
2009 1.060.882.497 58.73%
2010 1.478.181.458 28.23%
2011 1.602.789.529 7.77%
2012 2.094.865.990 23.49%
2013 2.328.717.164 10.04%
2014 2.597.104.303 10.33%
2015 3.156.270.749 17.72%
2016 3.864.895.456 18.33%
2017 4.167.391.907 7.26%
2018 4.616.658.037 9.73%
2019 4.984.426.490 7.38%
2020 6.305.052.157 20.95%
2021 6.907.891.889 8.73%
2022 7.631.643.912 9.48%
2023 7.444.681.386 -2.51%
2023 7.970.195.347 6.59%
2024 8.039.789.740 0.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Renhe Pharmacy Co., Ltd. Liabilities
Year Liabilities Growth
1993 116.742.905
1994 124.083.524 5.92%
1995 119.535.306 -3.8%
1996 126.671.106 5.63%
1997 118.758.556 -6.66%
1998 126.299.984 5.97%
1999 214.724.451 41.18%
2000 306.290.956 29.9%
2001 380.359.349 19.47%
2002 420.925.484 9.64%
2003 441.209.319 4.6%
2004 431.681.247 -2.21%
2005 409.115.088 -5.52%
2006 77.014.007 -431.22%
2007 73.043.886 -5.44%
2008 132.201.282 44.75%
2009 203.720.107 35.11%
2010 566.132.843 64.02%
2011 460.680.449 -22.89%
2012 382.800.772 -20.34%
2013 389.863.610 1.81%
2014 435.058.773 10.39%
2015 555.411.108 21.67%
2016 660.413.958 15.9%
2017 694.946.933 4.97%
2018 701.674.073 0.96%
2019 632.470.080 -10.94%
2020 694.536.400 8.94%
2021 980.999.158 29.2%
2022 1.209.855.727 18.92%
2023 752.888.902 -60.7%
2023 1.168.773.229 35.58%
2024 971.758.559 -20.27%

Renhe Pharmacy Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.38
Net Income per Share
0.4
Price to Earning Ratio
16.78x
Price To Sales Ratio
1.96x
POCF Ratio
10.99
PFCF Ratio
16.05
Price to Book Ratio
1.46
EV to Sales
1.81
EV Over EBITDA
9.5
EV to Operating CashFlow
10.13
EV to FreeCashFlow
14.8
Earnings Yield
0.06
FreeCashFlow Yield
0.06
Market Cap
9,19 Bil.
Enterprise Value
8,48 Bil.
Graham Number
6.36
Graham NetNet
2.62

Income Statement Metrics

Net Income per Share
0.4
Income Quality
1.53
ROE
0.09
Return On Assets
0.07
Return On Capital Employed
0.1
Net Income per EBT
0.62
EBT Per Ebit
1.2
Ebit per Revenue
0.16
Effective Tax Rate
0.3

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.36
Operating Profit Margin
0.16
Pretax Profit Margin
0.19
Net Profit Margin
0.12

Dividends

Dividend Yield
0.03
Dividend Yield %
3.01
Payout Ratio
0
Dividend Per Share
0.2

Operating Metrics

Operating Cashflow per Share
0.6
Free CashFlow per Share
0.41
Capex to Operating CashFlow
0.32
Capex to Revenue
0.06
Capex to Depreciation
11.12
Return on Invested Capital
0.08
Return on Tangible Assets
0.08
Days Sales Outstanding
64.92
Days Payables Outstanding
22.9
Days of Inventory on Hand
49.95
Receivables Turnover
5.62
Payables Turnover
15.94
Inventory Turnover
7.31
Capex per Share
0.19

Balance Sheet

Cash per Share
2,72
Book Value per Share
5,11
Tangible Book Value per Share
4.41
Shareholders Equity per Share
4.55
Interest Debt per Share
0.2
Debt to Equity
0.04
Debt to Assets
0.03
Net Debt to EBITDA
-0.8
Current Ratio
5.24
Tangible Asset Value
6,11 Bil.
Net Current Asset Value
4,11 Bil.
Invested Capital
6471974969
Working Capital
4,11 Bil.
Intangibles to Total Assets
0.12
Average Receivables
0,84 Bil.
Average Payables
0,18 Bil.
Average Inventory
377440301
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Renhe Pharmacy Co., Ltd. Dividends
Year Dividends Growth
2001 0
2010 0 0%
2011 0 0%
2012 0 0%
2014 0 0%
2015 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Renhe Pharmacy Co., Ltd. Profile

About Renhe Pharmacy Co., Ltd.

Renhe Pharmacy Co., Ltd. produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, topical lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in 1996 and is headquartered in Nanchang, China.

CEO
Mr. Qiu Lin Peng
Employee
5.792
Address
No. 998, Honggu Middle Avenue
Nanchang, 330038

Renhe Pharmacy Co., Ltd. Executives & BODs

Renhe Pharmacy Co., Ltd. Executives & BODs
# Name Age
1 Mr. Feng Jiang
Secretary of the Board & Non-Independent Director
70
2 Mr. Qiu Lin Peng
Chief Financial Officer & Non-Independent Director
70
3 Mr. Zi Qiang Zhang
Deputy GM & Employee Director
70

Renhe Pharmacy Co., Ltd. Competitors